drugset / Trial / NCT07266298
TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors
NaSequentialOpen-labelTreatment
Summary
This clinical trial is a prospective, dose-escalation, multicenter, single- arm, Phase 1 clinical trial to evaluate the safety, tolerability, PK and preliminary clinical activity of PRAME Antigen-targeted TCR-T Cells (NW-101C) infusion in patients with previously heavily treated, metastatic solid malignant tumors.
Timeline
- Start
- 2025-12
- Primary completion
- 2028-12
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NW-101C | Cell therapy | 4e+08 cells | Other |
| Subject | NW-101C | Cell therapy | 8e+08 cells | Other |
| Subject | NW-101C | Cell therapy | 1.5e+09 cells | Other |
| Subject | NW-101C | Cell therapy | 3e+09 cells | Other |